Skip to main content

Participate in a Trial

Start your journey

A clinical trial is a research study that is done to find out if a study treatment is safe and effective.  A study treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise.

We have opportunities to help with studies of these rare conditions.

NCT03473223 | Phase 3 | Interventional

Acute Coronary Syndrome

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

161 Sites
18200 Participants
18 Years
NCT03805789 | Phase 2 | Interventional

Acute-graft-versus-host Disease

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

11 Sites
310 Participants
12 Years
NCT03744910 | Phase 3 | Interventional

Antibody-mediated Rejection

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

21 Sites
350 Participants
18 Years to 75 Years
NCT04044690 | Phase 3 | Interventional


A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

13 Sites
126 Participants
18 Years
NCT04419467 | Phase 2 | Interventional

Diabetic Kidney Disease (DKD)

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

19 Sites
100 Participants
25 Years
NCT04167514 | Phase 3 | Interventional

Graft Versus Host Disease (GVHD)

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

25 Sites
122 Participants
18 Years
NCT05130970 | Phase 2 | Interventional

Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

19 Sites
80 Participants
40 Years
NCT05422326 | Phase 2 | Interventional

Influenza, Human

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

18 Sites
300 Participants
18 Years
NCT05501561 | Phase 2 | Interventional

Influenza, Human

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

47 Sites
1000 Participants
50 Years
NCT03684018 | Phase 4 | Interventional

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Two Dose Levels of Privigen in Pediatric CIDP

7 Sites
30 Participants
2 Years to 17 Years
NCT04285827 | Phase 1 | Interventional

Sickle Cell Disease

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

6 Sites
32 Participants
18 Years to 60 Years